SCHEMBL3722703

SCHEMBL3722703

CCCC[Sn](CCCC)(CCCC)c1ccc(C(=O)OC)c(C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.43
ALDH1A1 P00352 7/20 0.43
HPGD P15428 3/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MGLL Q99685 1/20 0.39
MAPT P10636 3/20 0.39
GAA P10253 3/20 0.39
HSD17B10 Q99714 3/20 0.39
CASP1 P29466 2/20 0.39
GLA P06280 2/20 0.39
CASP7 P55210 1/20 0.39
ATM Q13315 1/20 0.39
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C19 P33261 1/20 0.37
KMT2A Q03164 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5952565 0.80 NPC1 (0.50) ALDH1A1HPGDL3MBTL1MGLLMAPT
SCHEMBL2720868 0.79 PTPN11 (0.46) KDM4EALDH1A1HPGDL3MBTL1MGLL
SCHEMBL6570768 0.77 KDM4E (0.44) KDM4EALDH1A1HPGDL3MBTL1MGLL
SCHEMBL13164008 0.75 THRB (0.56) KDM4EALDH1A1HPGDL3MBTL1MAPT
SCHEMBL15498456 0.75 PPARA (0.50) KDM4EALDH1A1HPGDL3MBTL1MAPT
SCHEMBL28446209 0.74 CYP4A11 (0.48) ALDH1A1MGLLMAPTCASP1SMN1; SMN2
SCHEMBL1454369 0.73 CA1 (0.54) ALDH1A1HPGDMAPTLMNASMN1; SMN2
SCHEMBL16487411 0.72 PPARA (0.58)
SCHEMBL20503379 0.72 PPARA (0.58)
SCHEMBL6570774 0.72 PLA2G2A (0.41) KDM4EALDH1A1HPGDL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305093-A1 Inhibitors of mTOR and Methods of Making and Using EXELIXIS, INC. (US) 2010-12-02 US disclosed
WO-2010118208-A1 BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER EXELIXIS, INC. (US) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305093-A1 Inhibitors of mTOR and Methods of Making and Using MTOR, RICTOR, RPTOR KDM4E 718/4885ALDH1A1 3391/4885HPGD 1748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.